Currently, other potential targets are being extensively studied to broaden our understanding of EMPD treatment options, including androgen receptor 31–34, programmed death 1/programmed death-ligand 1 35–37, cyclin-dependent kinase 4 38, C-X-C chemokine receptor type 4 (CXCR4), CXCR7 39, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) 40, dynamin-related protein 1 (DRP1) 41, nectin cell adhesion molecule 4 (NECTIN4) 42,43, trophoblast cell surface antigen 2 (TROP2) 44, and forkhead box A1 (FOXA1) 45. The gene discussed is TACSTD2; the disease is extramammary Paget disease.